Role of biosimilar introduction on insulin glargine prices: a retrospective analysis in 28 European countries
Objective Quantify insulin glargine prices following the market introduction of biosimilars. Examine price levels and price changes for originator and biosimilars, by country.Methods Retrospective quantitative analysis using insulin glargine pricing data, both of the originator product and its biosi...
Saved in:
Main Authors: | David Beran, Margaret Ewen, Mario Raviglione, Tido von Schoen-Angerer, Davide Morolla |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-01-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/15/1/e090484.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Insulin Detemir Causes Lesser Weight Gain in Comparison to Insulin Glargine: Role on Hypothalamic NPY and Galanin
by: Mohammad Ishraq Zafar, et al.
Published: (2014-01-01) -
Cost Effectiveness of Insulin Glargine versus Neutral Protamin Hagedorn Insulin in the Treatment of Type 2 Diabetes Patients in Turkey
by: Ilhan Satman, et al.
Published: (2013-08-01) -
A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes
by: Shuo Lin, et al.
Published: (2018-01-01) -
Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia
by: Mohammed Alqahtani, et al.
Published: (2024-11-01) -
Confidence Region Approach for Assessing Bioequivalence and Biosimilarity Accounting for Heterogeneity of Variability
by: Jianghao Li, et al.
Published: (2015-01-01)